В статье обсуждаются вопросы рациональной фармакотерапии артериальной гипертензии, а также роль современных антагонистов кальция в фармакотерапии артериальной гипертензии и ассоциированных состояний.
The paper discusses the issues of rational pharmacotherapy for hypertension and the role of current calcium antagonists in pharmacotherapy for hypertension and associated conditions.
1. Крюков Н.Н., Качковский М.А., Бабанов С.А., Вербовой А.Ф. Справочник терапевта. Ростов-на-Дону: Феникс, 2013.
2. Kannel WB, Dawler TR, Mac Gee DL. Perspectives on systolic hypertension: the Framingham Study. Circulation 1985; 61: 1179–82.
3. Косарев В.В., Бабанов С.А., Вербовой А.Ф. Справочник клинического фармаколога. Ростов-на-Дону: Феникс, 2011.
4. Mancia G, De Backer G, Dominiczak A et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology (2007). Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105–87.
5. Toyo-Oka T, Nayler W. Third generation calcium entry blockers. Blood Press 1996; 5 (4): 206–8.
6. Watts RW et al. A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essentional hypertension using 24-h ambulatory monitoring. Blood Press 1998; 7 (1): 25–30.
7. Kloner RA et al. Sex- and age-related antihypertensive effect of amlodipine. Am J Card 1996; 77: 713–22.
8. Maior Outcomes in High-Risk Hypertensive Patients Randomised to Angiotensin–Converting Ensyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMMA 2002; 288 (23): 2981–98.
9. Horwitz LD et al. Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension. Am J Hypertens 1997; 10 (11): 1263–9.
10. Leenen FH et al. Persistence of antihypertensive effect after missed doses of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. British J Clin Pharmacol 1996; 41 (2): 83–8.
11. Hayduk K et al. Is initial dose titration of amlodipine worthwhile in patients with mild to moderate hypertension? Current Med Res Opinion 1999; 15 (1): 39–45.
12. De Champlain J et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998; 16 (11): 1357–69.
13. Petkar S et al. Amlodipine monotherapy in stable angina pectoris. Indian Heart J 1994; 46 (2): 85–8.
14. Steffensen R et al. Effects of amlodipine and isosorbide dinitrate on exercise–induced and ambulatory ischemia in patients with chronic stable angina pectoris. Cardiovasc Drug Ther 1997; 11 (5): 629–35.
15. Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698–706.
16. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
17. Van Kham et al. Amlodipine versus diltiazem controlled release as monotherapy in patients with stable coronary artery disease. Current Ther Res Clin Exp 1998; 59 (3): 139–48.
18. Deanfield J, Detry JM, Lichtlen PR. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind circadian anti-ischemia program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24: 1460–7.
19. Hall RJ. A multicentral study comparing the efficacy and tolerability of nisoldipine coat-core and amlodipine in patients with chronic stable angina. Current Ther Res Clin Exp 1998; 59 (7): 483–97.
20. Pitt B, Byington R, Furberg C et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503–10.
21. Nissen SE, Tuzcu EM, Libby P. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
22. Preston RA, Harvey P, Herfert O et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007; 47 (12): 1555–69.
23. Messerli FH, Bakris GL, Ferrera D et al. AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006; 8 (8): 571–83.
24. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14.
25. Dahlof B, Sever PS, Poulter NR for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
26. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes. Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006; 113: 1213–25.
27. Pepine C, Handberg EM, Cooper de Hoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.
28. Карпов ЮА. Применение антагонистов кальция у больных артериальной гипертонией и ишемической болезнью сердца: современное состояние вопроса. Кардиология. 2000; 10: 52–5.
Авторы
В.В.Косарев, С.А.Бабанов*
ГБОУ ВПО Самарский государственный медицинский университет Минздрава России
*s.a.babanov@mail.ru
________________________________________________
V.V.Kosarev, S.A.Babanov*
Samara State Medical University, Ministry of Health of Russia
*s.a.babanov@mail.ru